We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old female with metastatic renal cell cancer on oral tyrosine kinase inhibitor cabozantinib, was brought into the emergency room because of confusion and seizures, found to have elevated blood pressure and atypical MRI findings consistent with PRES due to cabozantinib.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506375PMC
http://dx.doi.org/10.1159/000509640DOI Listing

Publication Analysis

Top Keywords

oral tyrosine
12
tyrosine kinase
12
kinase inhibitor
12
inhibitor cabozantinib
12
atypical posterior
8
posterior reversible
8
reversible encephalopathy
8
encephalopathy syndrome
8
cabozantinib case
8
syndrome oral
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!